- CA$1.15bn
- CA$1.06bn
- CA$450.09m
Brief: Knight Therapeutics - Launches Tavalisse In Brazil For Chronic Immune Thrombocytopenia
Brief: Knight Therapeutics Enters Into Exclusive Distribution Agreement With Kyowa Kirin International For Poteligeo® (Mogamulizumab)
Brief: Knight Therapeutics Announces Regulatory Approval Of Tavalisse® In Colombia
Brief: Knight Therapeutics Announces Supplemental Regulatory Submission For Minjuvi In Brazil
Canada's Knight Therapeutics Q2 revenue beats on growth in promoted portfolio
Brief: Knight Therapeutics Q2 Revenue CAD 144.212 Million Vs. IBES Estimate CAD 125 Million
Brief: Knight Therapeutics Announces Repayment Of Revolving Credit Facility
Brief: Knight Therapeutics Announces Launch Of Tavalisse® In Mexico
Canada Research Roundup: Aritzia, Knight Therapeutics, WSP Global
Canada's Knight Therapeutics Q1 revenue jumps 69%, beats estimates
Canada's Knight Therapeutics Q4 revenue beats estimates on acquisitions strength
Brief: Knight Therapeutics Q4 Revenue CAD 133.106 Million Vs. IBES Estimate CAD 117.3 Million
Brief: Knight Therapeutics Announces Regulatory Supplemental Submission Of Minjuvi® (Tafasitamab) For Follicular Lymphoma In Argentina And Mexico
Brief: Knight Therapeutics Announces Approval Of Additional Indication For Minjuvi® (Tafasitamab) In Brazil
Brief: Knight Therapeutics Announces Health Canada Approval For Wynzora®
Knight Therapeutics Q3 revenue up 32%, beats estimates
Brief: Knight Announces Closing Of Us$100 Million Revolving Credit Facility
Brief: Knight Therapeutics Announces Relaunch of ORGOVYX® in Canada
Brief: Knight Therapeutics Announces Relaunch Of Myfembree® In Canada